文献速递艾滋病与性传播感染

撒哈拉以南非洲儿童HIV治疗前耐药惊人增加:系统综述与荟萃分析

Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-analysis.
PubMed 文献 · J Antimicrob Chemother · 2016-12-20

该系统综述纳入19项研究、2617名来自13个国家的儿童,评估撒哈拉以南非洲儿童HIV治疗前耐药(PDR)的流行情况。荟萃分析显示,暴露于PMTCT的儿童PDR合并患病率为42.7%(95%CI 26.2%-59.1%),未暴露儿童为12.7%(95%CI 6.7%-18.7%)(P=0.004)。未暴露儿童PDR从2004年的0%上升至2013年的26.8%(P=0.009),提示PDR在非洲儿童中高且快速增加。

要点

  • PMTCT暴露儿童PDR合并患病率42.7%,未暴露儿童12.7%。
  • 未暴露儿童PDR从2004年0%升至2013年26.8%。
  • <3岁儿童PDR高于≥3岁儿童(40.9% vs 17.6%)。

核心结论

  • 非洲儿童PDR患病率高且快速增加,即使PMTCT未暴露儿童最新报告PDR也可高达三分之一。
  • 数据强调<3岁幼儿应启动以PI为基础的一线ART,并提示年长儿童也可能受益。

研究设计与样本

  • 系统综述与随机效应荟萃分析,纳入19项研究、2617名来自13个国家的儿童(中位年龄≤12岁)。
  • 分别提取有和无PMTCT暴露儿童的PDR比例,用meta回归评估亚组差异。

主要发现

  • PMTCT暴露儿童PDR合并患病率42.7%(95%CI 26.2%-59.1%),未暴露儿童12.7%(95%CI 6.7%-18.7%)(P=0.004)。
  • 未暴露儿童PDR从2004年0%增至2013年26.8%(P=0.009)。
  • NNRTI突变在暴露儿童中占32.4%(95%CI 18.7%-46.1%),未暴露儿童中占9.7%(95%CI 4.6%-14.8%);PI突变不常见(<2.5%)。
  • PDR在<3岁儿童中更常见:40.9%(95%CI 27.6%-54.3%)vs ≥3岁儿童17.6%(95%CI 8.9%-26.3%)(P=0.025)。

临床怎么用

  • 对撒哈拉以南非洲<3岁幼儿启动一线ART时应优先选择以PI为基础的方案。
  • 年长儿童也可能从以PI为基础的一线ART中获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Children have an augmented risk of pretreatment HIV drug resistance (PDR) due to exposure to antiretroviral drugs for the prevention of mother-to-child transmission (PMTCT). Paediatric data are essential to evaluate the effectiveness of the restricted number of paediatric regimens currently available, but these data are scarce. METHODS: We conducted a systematic review of the literature on PDR in children (median age ≤12 years) in sub-Saharan Africa. We separately extracted the proportion of children with PDR for children with and without prior PMTCT exposure, used random-effects meta-analysis to pool proportions and used meta-regression to assess subgroup differences. RESULTS: We included 19 studies representing 2617 children from 13 countries. The pooled PDR prevalence was 42.7% (95% CI 26.2%-59.1%) among PMTCT-exposed children and 12.7% (95% CI 6.7%-18.7%) among PMTCT-unexposed children (P = 0.004). The PDR prevalence in PMTCT-unexposed children increased from 0% in 2004 to 26.8% in 2013 (P = 0.009). NNRTI mutations were detected in 32.4% (95% CI 18.7%-46.1%) of PMTCT-exposed children and in 9.7% (95% CI 4.6%-14.8%) of PMTCT-unexposed children; PI mutations were uncommon (<2.5%). PDR was more common in children aged <3 years compared with children aged ≥3 years [40.9% (95% CI 27.6%-54.3%) versus 17.6% (95% CI 8.9%-26.3%), respectively (P = 0.025)]. CONCLUSIONS: The PDR prevalence in African children is high and rapidly increasing. Even in PMTCT-unexposed children, the most recent reports indicate that PDR is present in up to a third of children starting first-line therapy. Our data underscore the importance of initiating PI-based first-line ART in young children (<3 years of age) and suggest that older children may also benefit from this approach.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Boerma RS, Sigaloff KC, Akanmu AS, et al. Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-analysis. J Antimicrob Chemother. 2016. PMID: 27999070. doi:10.1093/jac/dkw463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。